26361 Invitae Breast Cancer STAT Panel (50001)

All genes on this panel have published medical management guidelines and are associated with defined hereditary cancer syndromes.

This test is appropriate for breast cancer patients with upcoming cancer-related breast surgeries and/or treatment where genetic testing may inform decisions such as lumpectomy versus mastectomy, single versus double mastectomy, or use of other treatments (such as use of PARP inhibitors or other chemotherapy regimens). Identification of a disease-causing variant may also guide testing and management of at-risk relatives. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations in tumor tissue.

Blood should be shipped overnight at room temperature. 

​Store saliva at room temperature, avoiding lengthy refrigeration. Although there are no special time requirements, we recommend that the specimen be mailed to Invitae soon after collection.

Saliva collected and stored in an Oragene^TM self collection kit (OG500/OGD500/OGD510)

• Please note that this kit requires 2 mL of saliva for OG500/OGD500 and 1 mL of saliva for OGD510, and involves active (not assisted) saliva donation.

​The Invitae Breast Cancer STAT Panel includes up to 9 well-established genes that are associated with a significantly increased risk of developing breast cancer. Accelerated turnaround time (TAT) is needed because physicians and patients often want to make surgical and management decisions as quickly as possible. Individuals who are identified with an inherited pathogenic variant have a higher risk of developing another breast cancer and may choose more aggressive surgery and/or different treatment options based on genetic testing results.

All genes on this panel have published medical management guidelines and are associated with defined hereditary cancer syndromes.

This test is appropriate for breast cancer patients with upcoming cancer-related breast surgeries and/or treatment where genetic testing may inform decisions such as lumpectomy versus mastectomy, single versus double mastectomy, or use of other treatments (such as use of PARP inhibitors or other chemotherapy regimens). Identification of a disease-causing variant may also guide testing and management of at-risk relatives. This test is specifically designed for heritable germline mutations and is not appropriate for the detection of somatic mutations in tumor tissue.

An interpretive report will be provided

​An interpretive report will be provided